CRSP vs. MRNA, NBIX, EXEL, TECH, PCVX, QGEN, RGEN, HALO, RVMD, and KRYS
Should you be buying CRISPR Therapeutics stock or one of its competitors? The main competitors of CRISPR Therapeutics include Moderna (MRNA), Neurocrine Biosciences (NBIX), Exelixis (EXEL), Bio-Techne (TECH), Vaxcyte (PCVX), Qiagen (QGEN), Repligen (RGEN), Halozyme Therapeutics (HALO), Revolution Medicines (RVMD), and Krystal Biotech (KRYS). These companies are all part of the "biological products, except diagnostic" industry.
CRISPR Therapeutics vs.
CRISPR Therapeutics (NASDAQ:CRSP) and Moderna (NASDAQ:MRNA) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, earnings, media sentiment, valuation, risk, community ranking and dividends.
Moderna has a net margin of -110.04% compared to CRISPR Therapeutics' net margin of -981.54%. CRISPR Therapeutics' return on equity of -18.46% beat Moderna's return on equity.
69.2% of CRISPR Therapeutics shares are held by institutional investors. Comparatively, 75.3% of Moderna shares are held by institutional investors. 4.1% of CRISPR Therapeutics shares are held by insiders. Comparatively, 11.0% of Moderna shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
CRISPR Therapeutics has a beta of 1.77, indicating that its stock price is 77% more volatile than the S&P 500. Comparatively, Moderna has a beta of 1.86, indicating that its stock price is 86% more volatile than the S&P 500.
CRISPR Therapeutics received 265 more outperform votes than Moderna when rated by MarketBeat users. Likewise, 64.43% of users gave CRISPR Therapeutics an outperform vote while only 53.88% of users gave Moderna an outperform vote.
CRISPR Therapeutics currently has a consensus target price of $73.11, suggesting a potential upside of 71.53%. Moderna has a consensus target price of $59.00, suggesting a potential upside of 72.67%. Given Moderna's higher possible upside, analysts plainly believe Moderna is more favorable than CRISPR Therapeutics.
CRISPR Therapeutics has higher earnings, but lower revenue than Moderna. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.
In the previous week, Moderna had 8 more articles in the media than CRISPR Therapeutics. MarketBeat recorded 18 mentions for Moderna and 10 mentions for CRISPR Therapeutics. CRISPR Therapeutics' average media sentiment score of 0.71 beat Moderna's score of 0.35 indicating that CRISPR Therapeutics is being referred to more favorably in the media.
Summary
CRISPR Therapeutics beats Moderna on 10 of the 19 factors compared between the two stocks.
Get CRISPR Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRSP and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
CRISPR Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:CRSP) was last updated on 3/25/2025 by MarketBeat.com Staff
Buy CRSP Stock Free CRSP Stock Alerts